Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Please provide your email address to receive an email when new articles are posted on . Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute ...
Hosted on MSN
Quest launches flow cytometry MRD test for myeloma
Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells. The test aims to enhance ultra-sensitive ...
In this roundtable webinar, discover how scientists improve tumor-informed minimal residual disease (MRD) testing for ...
Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity. Measurable residual disease (MRD ...
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics. Testing for minimal residual disease ...
The Precise MRD test is Myriad’s tumor-informed circulating tumor DNA (ctDNA) assay designed to support longitudinal monitoring during cancer treatment. Using whole-genome sequencing to create a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results